The Centers for Disease Control and Prevention has quietly altered the way it talks about childhood vaccines, and the shift matters more than the bureaucratic language suggests. Under Robert F. Kennedy Jr.’s leadership at the Department of Health and Human Services, the CDC now endorses “shared decision-making” for routine childhood immunizations — a framework that sounds reasonable on its face but effectively downgrades decades of firm public health recommendations to something closer to suggestions.
Here’s what happened. In early 2025, the CDC’s Advisory Committee on Immunization Practices began revising its language around several childhood vaccines, moving away from universal recommendations toward a model where parents and physicians discuss whether to vaccinate on a case-by-case basis. As Wired reported, this isn’t a minor rhetorical tweak. Shared decision-making, in clinical practice, is typically reserved for situations where the evidence is genuinely uncertain or where individual risk-benefit calculations vary significantly — cancer screenings for certain age groups, for instance, or elective procedures. Applying it to vaccines with established safety and efficacy profiles is something else entirely.
It’s a policy laundered through the vocabulary of patient autonomy.
The distinction between a universal recommendation and shared decision-making has measurable downstream effects. When ACIP issues a universal recommendation, insurers are required under the Affordable Care Act to cover the vaccine without cost-sharing. When the recommendation shifts to shared decision-making, that mandate can evaporate. Families could face out-of-pocket costs. Pediatricians lose a clear protocol. School immunization requirements, which are tied to CDC recommendations in many states, become legally ambiguous. And vaccination rates, which have already been declining in parts of the country, face another structural headwind.
The numbers are already concerning. According to CDC data published in late 2024, kindergarten vaccination coverage for the 2023-2024 school year dropped to approximately 92.7% nationally for the MMR vaccine — below the 95% threshold generally considered necessary for herd immunity against measles. Exemption rates hit 3.3%, the highest ever recorded. That was before the current policy changes took effect.
The measles situation provides a concrete case study. The United States saw 284 confirmed measles cases in the first four months of 2025, according to figures tracked by the CDC, concentrated in outbreaks in Texas, New Mexico, and parts of the Midwest. A significant outbreak in West Texas, centered in communities with low vaccination rates, resulted in multiple pediatric hospitalizations. Measles had been declared eliminated from the U.S. in 2000. That status now looks fragile.
So what does shared decision-making actually look like in a pediatrician’s office? In theory, the doctor presents risks and benefits, the parent asks questions, and together they arrive at a decision. In practice, it creates an opening for misinformation to carry equal weight with clinical evidence. A parent who has watched anti-vaccine content on social media walks in with a set of beliefs. The physician, now stripped of the authority to say “the CDC universally recommends this,” is left to negotiate. Time-pressed appointments — the average pediatric visit runs 15 to 18 minutes — don’t allow for the kind of thorough conversation this model demands.
Physicians know this. The American Academy of Pediatrics has pushed back firmly, stating that universal vaccine recommendations should remain the standard for immunizations with well-established safety profiles. Dr. Sean O’Leary, a pediatric infectious disease specialist at the University of Colorado and former chair of the AAP’s Committee on Infectious Diseases, told Wired that shared decision-making for routine childhood vaccines “doesn’t make sense from a scientific standpoint.”
He’s right. And the reasoning is straightforward.
Shared decision-making is appropriate when there’s genuine clinical equipoise — when the evidence doesn’t clearly favor one path over another. For childhood vaccines like MMR, DTaP, and polio, there is no equipoise. The evidence overwhelmingly supports vaccination. The risks of the diseases dwarf the risks of the vaccines. Decades of surveillance data, involving hundreds of millions of doses, confirm this. Framing the decision as a coin flip between two equally valid options is scientifically dishonest, regardless of how it’s packaged.
But the framing serves a political purpose. Kennedy has spent years arguing that vaccines carry underappreciated risks, and his organization, Children’s Health Defense, has been one of the most prolific sources of anti-vaccine content online. As HHS secretary, he can’t outright ban vaccines or formally rescind recommendations without triggering immediate legal and political backlash. What he can do is erode the infrastructure of recommendation — soften the language, introduce ambiguity, shift the burden of decision onto individual families. Shared decision-making accomplishes this without a single dramatic headline.
The insurance implications alone could suppress vaccination rates among lower-income families. Under current ACA provisions, vaccines with a universal ACIP recommendation must be covered at no cost. If a vaccine moves to shared decision-making status, insurers may argue they’re no longer obligated to provide zero-cost coverage. A single dose of MMR vaccine costs roughly $70-$90 without insurance. For a family with multiple children and no coverage, that’s a real barrier. KFF has documented how even modest cost-sharing reduces preventive care uptake, particularly among Medicaid-eligible populations.
State-level effects will vary. Some states tie school entry requirements directly to ACIP universal recommendations. Others have independent mandates. But the signal from the federal government matters enormously. When the CDC hedges, state legislators who want to loosen vaccine requirements gain cover.
There’s a historical parallel worth examining. In the early 2000s, the UK saw a dramatic drop in MMR vaccination rates after Andrew Wakefield’s fraudulent 1998 study linking the vaccine to autism gained traction. Coverage fell below 80% in parts of London. Measles outbreaks followed predictably. It took over a decade to rebuild public confidence and restore vaccination rates. The UK experience demonstrated that once trust erodes, the recovery is slow, expensive, and marked by preventable illness and death.
The United States is now conducting a version of that experiment at federal scale.
Industry insiders should watch several indicators closely. First, ACIP meeting agendas and vote records — any further reclassifications of universally recommended vaccines to shared decision-making status will signal the direction of travel. Second, insurer coverage policies in response to changed recommendations. Third, state-level vaccination rate data, which the CDC publishes annually but which may face reporting delays or methodological changes under current leadership. And fourth, the legal challenges that will inevitably arise when families or advocacy groups contest changes to coverage mandates.
None of this is hypothetical. The policy changes are happening now, the measles outbreaks are happening now, and the erosion of a public health infrastructure that took decades to build is underway. Shared decision-making is a legitimate clinical tool in the right context. Applied to childhood vaccines with overwhelming evidence of safety and benefit, it’s not empowerment. It’s abandonment dressed in the language of choice.
The CDC’s credibility rests on its willingness to make clear, evidence-based recommendations even when those recommendations are politically inconvenient. That willingness is being tested. So far, it’s failing the test.
WebProNews is an iEntry Publication